Abstract
9052 Background: Ipilimumab (Ipi) improves the survival of patients (pts) with advanced melanoma. Combination of Ipi with an autologous monocyte-derived DC therapy (TriMixDC-MEL) may further improv...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have